Melanoma prognosis in Europe: Far from equal

British Journal of Dermatology

Volumn 171, Issue 1, 2014, Pages 179-182

  Forsea, A M ^a   Del Marmol, V ^b   Stratigos, A ^c   Geller, A C ^d  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CONTROLLED STUDY; CORRELATION COEFFICIENT; EASTERN EUROPE; EUROPE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; MORTALITY TO INCIDENCE RATIO; MULTICENTER STUDY; PRIORITY JOURNAL; PUBLIC HEALTH; WESTERN EUROPE; WORLD HEALTH ORGANIZATION; COHORT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; INCIDENCE; MORTALITY; PROGNOSIS; SKIN TUMOR; STATISTICS AND NUMERICAL DATA;

COHORT STUDIES; EUROPE; HEALTH EXPENDITURES; HUMANS; INCIDENCE; MELANOMA; PROGNOSIS; SKIN NEOPLASMS;

EID: 84904886077     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12923     Document Type: Article

References (14)

1. Curado MP, Edwards B, Shin HR, et al,. (eds). Cancer Incidence in Five Continents, vol. IX. IARC, no. 160. Lyon: International Agency for Research on Cancer, 2007.
2. Ferlay J, Shin HR, Bray F, et al,. Cancer Incidence and Mortality Worldwide, Globocan 2008 v1.2. IARC CancerBase No. 10 [online]. Lyon: International Agency for Research on Cancer, 2010. Available at: http://globocan.iarc.fr (last accessed 2 June 2014).
3. Sant M, Allemani C, Santaquilani M, et al,. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009; 45: 931-91.
4. de Vries E, Coebergh JW,. Cutaneous malignant melanoma in Europe. Eur J Cancer 2004; 40: 2355-66.
5. Forsea AM, Del Marmol V, de Vries E, et al,. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol 2012; 167: 1124-30.
6. Vercelli M, Lillini R, Capocaccia R, et al,. Cancer survival in the elderly: effects of socio-economic factors and health care system features (ELDCARE project). Eur J Cancer 2006; 42: 234-42.
7. Asadzadeh Vostakolaei F, Karim-Kos HE, Janssen-Heijnen ML, et al,. The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health 2010; 21: 573-7.
8. Hebert JR, Daguise VG, Hurley DM, et al,. Mapping cancer mortality-to-incidence ratios to illustrate racial and sex disparities in a high-risk population. Cancer 2009; 115: 2539-52.
9. Eide MJ, Weinstock MA, Clark MA,. The association of physician-specialty density and melanoma prognosis in the United States, 1988 to 1993. J Am Acad Dermatol 2009; 60: 51-8.
10. Geller AC, Miller DR, Lew RA, et al,. Cutaneous melanoma mortality among the socioeconomically disadvantaged in Massachusetts. Am J Public Health 1996; 86: 538-43.
11. Nicula FA, Anttila A, Neamtiu L, et al,. Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union. Eur J Cancer 2009; 45: 2679-84.
12. Kandolf-Sekulovic L, Zivkovic-Perisic S, Radevic T, et al,. Melanoma in South-East Europe: epidemiological data from the central cancer registry and clinicopathological characteristics from the hospital-based registry in Serbia. Int J Dermatol 2012; 51: 1186-94.
13. Lillini R, Vercelli M, Quaglia A, et al,. Use of socio-economic factors and healthcare resources to estimate cancer survival in European countries with partial national cancer registration. Tumori 2011; 97: 265-74.
14. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al,. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-403.